Many preclinical studies have confirmed the efficiency of PI3K/AKT/mTOR pathways-targeted chemicals on chemo-resistant osteosarcoma; however, only a few mTOR-targeted compounds succeeded in entering clinical trials currently. This evidence concerns the gene MTOR and osteosarcoma.